Fig. 2

Percentage of methylated reference as per [20] (Bettington et al. 2017), of BRAF mutant dysplastic sessile serrated adenomas (Left) and BRAF mutant colorectal cancers (Right) stratified for MLH1–93 genotype, and MLH1 protein immunostaining
Percentage of methylated reference as per [20] (Bettington et al. 2017), of BRAF mutant dysplastic sessile serrated adenomas (Left) and BRAF mutant colorectal cancers (Right) stratified for MLH1–93 genotype, and MLH1 protein immunostaining